reports
Kinder Morgan Inc: 1 director
A director at Kinder Morgan Inc sold 20,000 shares at 30.000USD and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to tw...
Lifecore Biomedical to be Added to Nasdaq Biotech Index
Lifecore Biomedical to be Added to Nasdaq Biotech Index CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company’s stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore’s inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025. The Nasdaq Biotechnology Index ...
Lifecore Biomedical Signs CDMO Master Services Agreement with New Larg...
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO master services agreement wit...
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthca...
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California. Details regarding Lifecore’s participation are as follows: 44th Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, includin...
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical to Participate in Upcoming Investor Conferences CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Jefferies 2025 Global Healthcare Conference – London Details: Paul Josephs, Lifecore’s president and chief executive officer, will deliver a corporate presentation and Lifecore management will parti...
- Jonathan Moreland
LNG CHENIERE ENERGY INC.
WM WASTE MANAGEMENT INC.
VRSK VERISK ANALYTICS INC
SLGN SILGAN HOLDINGS INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
OHI OMEGA HEALTHCARE INVESTORS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
NBTB NBT BANCORP INC.
MTDR MATADOR RESOURCES COMPANY
MNRO MONRO INC
JBLU JETBLUE AIRWAYS CORPORATION
GBCI GLACIER BANCORP INC.
FISV FISERV INC.
FFIN FIRST FINANCIAL BANKSHARES INC
DENN DENNY'S CORPORATION
CNS COHEN & STEERS INC.
AMT AMERICAN TOWER CORPORATION
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
NCBS NICOLET BANKSHARES INC
RLMD RELMADA THERAPEUTICS
URE UR-ENERGY
KMI KINDER MORGAN INC CLASS P
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
NSC NORFOLK SOUTHERN CORPORATION
AJG ARTHUR J. GALLAGHER & CO.
WINA WINMARK CORP.
FND FLOOR & DECOR HOLDINGS INC. CLASS A
BX THE BLACKSTONE GROUP L.P.
MBIN MERCHANTS BANCORP
OBNK ORIGIN BANCORP
OSPN ONESPAN
FUSB FIRST US BANCSHARES INC
AVO MISSION PRODUCE
UTZ UTZ BRANDS INC (A)
OPCH OPTION CARE HEALTH INC
INTA INTAPP INC
CLVT CLARIVATE PLC
NVCT NUVECTIS PHARMA INC
BPRN BANK OF PRINCETON
GTE GRAN TIERRA ENERGY INC.
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
GAM GENERAL DE ALQUILER DE MAQUINARIA
LAW CS DISCO INC
GF THE NEW GERMANY FUND
ASST INC.
ASSET ENTITIES INC.
Lifecore Biomedical Reports Financial Results for the Three Months End...
Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update -- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development an...
- Jonathan Moreland
USNA USANA HEALTH SCIENCES INC.
SLGN SILGAN HOLDINGS INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
MTDR MATADOR RESOURCES COMPANY
MOFG MIDWESTONE FINANCIAL GROUP
FISV FISERV INC.
FFIN FIRST FINANCIAL BANKSHARES INC
ARCC ARES CAPITAL CORPORATION
ASA ASA
NEWT NEWTEK BUSINESS SERVICES INC.
NCBS NICOLET BANKSHARES INC
KMI KINDER MORGAN INC CLASS P
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
AJG ARTHUR J. GALLAGHER & CO.
FND FLOOR & DECOR HOLDINGS INC. CLASS A
MBIN MERCHANTS BANCORP
CLVT CLARIVATE PLC
GF THE NEW GERMANY FUND
INC.
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
MAN MANPOWERGROUP
LII LENNOX INTERNATIONAL INC.
ITW ILLINOIS TOOL WORKS INC.
LNG CHENIERE ENERGY INC.
ABM ABM INDUSTRIES INCORPORATED
VRSK VERISK ANALYTICS INC
TYL TYLER TECHNOLOGIES INC.
TXN TEXAS INSTRUMENTS INCORPORATED
TNET TRINET GROUP INC.
RHI ROBERT HALF INTERNATIONAL INC.
KMB KIMBERLY-CLARK CORPORATION
FFIV F5 NETWORKS INC.
FDS FACTSET RESEARCH SYSTEMS INC.
FAST FASTENAL COMPANY
EXPO EXPONENT INC.
EEFT EURONET WORLDWIDE INC.
DECK DECKERS OUTDOOR CORPORATION
CLX CLOROX COMPANY
CL COLGATE-PALMOLIVE COMPANY
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
APOG APOGEE ENTERPRISES INC.
ALSN ALLISON TRANSMISSION HOLDINGS INC.
ADP AUTOMATIC DATA PROCESSING INC.
WFT. WEST FRASER TIMBER CO. LTD.
LZB LAZBOY INCORPORATED
WM WALLBRIDGE MINING CO. LTD.
CWST CASELLA WASTE SYSTEMS INC. CLASS A
HNI HNI CORPORATION
RSG REPUBLIC SERVICES INC.
TREX TREX COMPANY INC.
AOS A. O. SMITH CORPORATION
GGG GIAIPHONG MOTOR JSC
LI LI AUTO INC. SPONSORED ADR CLASS A
HPK HIGHPEAK ENERGY INC (A)
UFPI UFP INDUSTRIES INC.
GFL GFL ENVIRONMENTAL INC
FOUR SHIFT4 PAYMENTS
ONON ON HLDNG AG
2VZ LEONARDO DRS INC.
KNF KNIFE RIVER CORPORATION
BIRK BIRKENSTOCK HOLDING PLC
CPAY CORPAY INC.
Lifecore Biomedical to Report Financial Results for the Three Months E...
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 Webcast Scheduled for Thursday, November 6 at 4:30 p.m. Eastern CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team ...
Lifecore Biomedical Selected as New Commercial Manufacturing Partner b...
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manuf...
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-...
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical custom...
Lifecore Biomedical to Participate at Upcoming Industry Conferences an...
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. Details of the company’s activities at these events are as follows: 15th Annual Partnership Opportunities in Drug Development (PODD)Conference Dates/Location: October 27-28, 2025, in Boston, MADetails: Ryan Swanson, Ph.D., Lifecore’s director of pro...
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(...
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Lifecore compensation committee approved the grant under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of a restricted stock unit (“RSU”) award with respect to 15,000 shares of its common stock and stock options for 30,000 shares of common stock to a newly hired em...
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Cont...
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 24th Annual Contract Pharma Contracting and Outsourcing Conference. Recognized as one of the top annual events for pharmaceutical outsourcing and contract manufacturing, the Contract Pharma conference will take place September 18-19, 2025, in New Brun...
Lifecore Biomedical to Participate in Upcoming Investor Conferences
Lifecore Biomedical to Participate in Upcoming Investor Conferences CHASKA, Minn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences. Details regarding Lifecore’s participation are as follows: Morgan Stanley 23rd Annual Global Healthcare ConferenceDetails: Lifecore management will participate in a fireside chat and in investor meetingsConference Dates: September 8-10, 2025Fireside...
Allison Transmission Holdings Inc: 1 director
A director at Allison Transmission Holdings Inc bought 3,000 shares at 89.500USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financ...
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update -- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics -- -- Improved Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, In...
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Fina...
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025 Webcast Scheduled for Thursday, August 7 at 4:30 p.m. Eastern CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and fiscal year 2025 on Thursday, August 7, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.